Unless operative vaginal delivery can be made at least as safe as cesarean delivery, it will be difficult to justify its continued existence. Proper technique is paramount.
Free CME Online
ACCREDITATION
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CME2, Inc. ("cme2 ") and Contemporary OB/GYN. cme2 is accredited by the ACCME to provide continuing medical education for physicians.
cme2 designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
EDUCATIONAL OBJECTIVES
After completing the following CME activity, the reader should be able to:
TO EARN CREDIT FOR THIS ACTIVITY
Participants should study the article and log onto http:// http://www.contemporaryobgyn.net/, where they must pass a post-test and complete an online evaluation of the CME activity. After passing the post-test and completing the online evaluation, a CME certificate will be e-mailed to them. The release date for this activity is May 1, 2007. The expiration date is May 1, 2008.
DISCLOSURES
Editors Elizabeth A. Nissen and Paul L. Cerrato disclose that they do not have any financial relationships with any manufacturer in this area of medicine.
The manuscript reviewer discloses that he is a retained consultant for Adeza Biomedical.
Dr. Hirsch discloses that he has no financial relationships with any manufacturer in this area of medicine.
RESOLUTION OF CONFLICT OF INTEREST
cme2 has implemented a process to resolve conflicts of interest for each continuing medical education activity, to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through a peer review process.
UNAPPROVED/OFF-LABEL USE DISCUSSION
Faculty may discuss information about pharmaceutical agents, devices, or diagnostic products that are outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Faculty are required to disclose any off-label discussion.
Operative vaginal delivery-which includes vaginal birth with the assistance of either forceps or vacuum devices-is one of the few remaining areas in obstetrics that may still be called an "art." But how long can it survive in an era of concerns about integrity of maternal tissues and short-and long-term maternal and fetal outcomes-a climate in which legal liability has contributed to ever-diminishing vaginal birth rates? Such concerns are amplified for operative (vs. nonoperative) vaginal delivery and threaten to eliminate the procedure from the armamentarium of newly trained obstetricians.
Compare trainees' experience with operative vaginal delivery to cesarean delivery. The Accreditation Council for Graduate Medical Education (ACGME) reports that in academic year 2005/2006, the national median for cesarean delivery cases per senior resident graduate over 4 years (either as primary operator or assistant) was 243 (ACGME Summary Report: Obstetrics; Residency Review Committee for Obstetrics and Gynecology, 2006). In contrast, the median 4-year experience for forceps was 11 cases and for vacuum extraction, 21. Most practitioners would agree that these numbers represent an inadequate level of training in operative vaginal delivery.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More